<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01138735</url>
  </required_header>
  <id_info>
    <org_study_id>RD.06.SPR.18155</org_study_id>
    <nct_id>NCT01138735</nct_id>
  </id_info>
  <brief_title>Epiduo Pediatric Acne Study</brief_title>
  <official_title>A Multi-center, Randomized, Vehicle-controlled, Double-blind, Study to Evaluate the Safety and Efficacy of Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Administered Once Daily for the Treatment of Subjects 9 to 11 Years of Age With Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of Epiduo® (adapalene and
      benzoyl peroxide) Gel 0.1%/2.5% administered once daily for up to 12 weeks in subjects 9 to
      11 years of age with acne vulgaris.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success Rate</measure>
    <time_frame>Baseline to Week 12 (Last Observation Carried Forward [LOCF])</time_frame>
    <description>Percentage of subjects rated Clear or Almost Clear with at least 2 grades reduction from Baseline on the Investigator's Global Assessment (IGA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Total Lesion Counts</measure>
    <time_frame>Baseline to Week 12 (LOCF)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Total Lesion Counts From Baseline</measure>
    <time_frame>Baseline to Week 12 (LOCF)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Inflammatory Lesion Counts From Baseline</measure>
    <time_frame>Baseline to Week 12 (LOCF)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">285</enrollment>
  <condition>Acne</condition>
  <arm_group>
    <arm_group_label>adapalene/benzoyl peroxide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5% applied topically once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical Gel Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topical Gel Vehicle applied topically once daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adapalene/benzoyl peroxide</intervention_name>
    <description>daily topical application for 12 weeks</description>
    <arm_group_label>adapalene/benzoyl peroxide</arm_group_label>
    <other_name>Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Gel Vehicle</intervention_name>
    <description>daily topical application for 12 weeks</description>
    <arm_group_label>Topical Gel Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of acne vulgaris with facial involvement

          -  Score of 3 (moderate) on the Investigator's Global Assessment (IGA) scale

          -  A minimum of 20 but not more than 100 total lesions (Noninflammatory and/or
             Inflammatory) on the face (including the nose) at Baseline

        Exclusion Criteria:

          -  Acne nodule or acne cyst

          -  Acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.),
             or severe acne requiring systemic treatment

          -  Underlying diseases and/or dermatologic conditions that require the use of interfering
             topical or systemic therapy or that might interfere with study assessments

          -  Use of prohibited medications prior to the study and/or are unwilling to refrain from
             such use during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Graeber, MD</last_name>
    <role>Study Director</role>
    <affiliation>Galderma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lorne Albrecht, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guildford Dermatology Specialists</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zoe Draelos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zoe Draelos, MD</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lawrence Eichenfield, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Childrens Hospital and Health Center Division of Pediatric and Adolescent Dermatology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Boni Elewski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UAB Dermatology Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alan Fleischer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Dermatology Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francisco Flores, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>FXM Research Miramar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Fowler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology Specialists Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Haber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haber Dermatology Clinical Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adelaide Hebert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Heffernan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Dermatology, PC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Kaplan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Adult &amp; Pediatric Dermatology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Kempers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Minnesota Clinical Study Center A Division of Associated Skin Care Specialist, PA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rodion Kunynetz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ultranova Skincare</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ian Landells, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nexus Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles Lynde, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lynderm Research Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Russell Mader, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology Associates of Kingsport, PC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lew Andrew Rosoph, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>North Bay Dermatology Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joel Schlessenger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skin Specialists, PC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Spigarelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Linda Stein Gold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henry Ford Health Systems - Department of Dermatology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey Sugarman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Redwood Family Dermatology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Werschler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Premier Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patricia Westmoreland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Palmetto Clinical Trial Services, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrea Zaenglein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State Milton S. Hershey Medical Center - Penn State College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Murakawa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermcenter PC; Somerset Skin Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB Dermatology Clinical Research</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Health Center Division of Pediatric and Adolescent Dermatology</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Redwood Family Dermatology</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FXM Research Miramar</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adult &amp; Pediatric Dermatology</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialists Research</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health Systems Department of Dermatology</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermcenter PC - Somerset Skin Centre</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Clinical Study Center A Division of Associated Skin Care Specialists, PA</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Dermatology PC</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Specialists, PC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zoe Draelos, MD</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology - Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cininnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haber Dermatology Clinical Research Center</name>
      <address>
        <city>South Euclid</city>
        <state>Ohio</state>
        <zip>44118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center - Penn State College of Medicine</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Clinical Trial Services, LLC</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates of Kingsport, PC</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Sciences Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guildford Dermatology Specialists</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 6A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nexus Clinical Research</name>
      <address>
        <city>St John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1A 5E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ultranova Skincare</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynderm Research, Inc</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Bay Dermatology Centre</name>
      <address>
        <city>North Bay</city>
        <state>Ontario</state>
        <zip>P1B 3Z7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2010</study_first_submitted>
  <study_first_submitted_qc>June 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2010</study_first_posted>
  <results_first_submitted>February 19, 2013</results_first_submitted>
  <results_first_submitted_qc>February 19, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 26, 2013</results_first_posted>
  <disposition_first_submitted>May 7, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>May 7, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 10, 2012</disposition_first_posted>
  <last_update_submitted>April 4, 2013</last_update_submitted>
  <last_update_submitted_qc>April 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benzoyl Peroxide</mesh_term>
    <mesh_term>Adapalene</mesh_term>
    <mesh_term>Adapalene, Benzoyl Peroxide Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Adapalene/Benzoyl Peroxide</title>
          <description>Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5% applied topically once daily for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Topical Gel Vehicle</title>
          <description>Topical Gel Vehicle applied topically once daily for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="142"/>
                <participants group_id="P2" count="143"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="134"/>
                <participants group_id="P2" count="126"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Adapalene/Benzoyl Peroxide</title>
          <description>Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5% applied topically once daily for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Topical Gel Vehicle</title>
          <description>Topical Gel Vehicle applied topically once daily for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="142"/>
            <count group_id="B2" value="143"/>
            <count group_id="B3" value="285"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="143"/>
                    <measurement group_id="B3" value="285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.3" spread="0.76"/>
                    <measurement group_id="B2" value="10.4" spread="0.68"/>
                    <measurement group_id="B3" value="10.4" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Success Rate</title>
        <description>Percentage of subjects rated Clear or Almost Clear with at least 2 grades reduction from Baseline on the Investigator's Global Assessment (IGA)</description>
        <time_frame>Baseline to Week 12 (Last Observation Carried Forward [LOCF])</time_frame>
        <population>Intent to treat (ITT) population, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Adapalene/Benzoyl Peroxide</title>
            <description>Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5% applied topically once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Topical Gel Vehicle</title>
            <description>Topical Gel Vehicle applied topically once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Success Rate</title>
          <description>Percentage of subjects rated Clear or Almost Clear with at least 2 grades reduction from Baseline on the Investigator's Global Assessment (IGA)</description>
          <population>Intent to treat (ITT) population, LOCF</population>
          <units>percentage of participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.2"/>
                    <measurement group_id="O2" value="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>null hypothesis: no difference in Success rate in two treatment groups (adapalene/benzoyl peroxide vs Topical Gel Vehicle).
power calculation: 90%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustment for multiplicity is required. The tests will be conducted as two-sided, each at the 0.05 significance level. The trial will be claimed ‘positive’ if all primary analyses are shown statistically significant at the 0.05 level.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel(CMH) test stratified by analysis center, using general association statistics</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Total Lesion Counts</title>
        <time_frame>Baseline to Week 12 (LOCF)</time_frame>
        <population>ITT population, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Adapalene/Benzoyl Peroxide</title>
            <description>Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5% applied topically once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Topical Gel Vehicle</title>
            <description>Topical Gel Vehicle applied topically once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Lesion Counts</title>
          <population>ITT population, LOCF</population>
          <units>lesion count change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.6" spread="22.43"/>
                    <measurement group_id="O2" value="-3.6" spread="24.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>null hypothesis: no difference in change from baseline in total lesion count in two treatment groups (adapalene/benzoyl peroxide vs Topical Gel Vehicle)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustment for multiplicity is required. The tests will be conducted as two-sided, each at the 0.05 significance level. The trial will be claimed ‘positive’ if all primary analyses are shown statistically significant at the 0.05 level.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>normality assumption is not met. ANCOVA Model: Ranked Change in Total Lesion Counts = Ranked Baseline Lesion Counts, Analysis Center, Treatment.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Total Lesion Counts From Baseline</title>
        <time_frame>Baseline to Week 12 (LOCF)</time_frame>
        <population>ITT Population, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Adapalene/Benzoyl Peroxide</title>
            <description>Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5% applied topically once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Topical Gel Vehicle</title>
            <description>Topical Gel Vehicle applied topically once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Total Lesion Counts From Baseline</title>
          <population>ITT Population, LOCF</population>
          <units>percentage of change in lesion count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-55.5" spread="38.99"/>
                    <measurement group_id="O2" value="-9.3" spread="48.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test with row mean difference statistic using relative to an identified distribution(RIDIT) score, controlling for analysis center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Inflammatory Lesion Counts From Baseline</title>
        <time_frame>Baseline to Week 12 (LOCF)</time_frame>
        <population>ITT Population, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Adapalene/Benzoyl Peroxide</title>
            <description>Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5% applied topically once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Topical Gel Vehicle</title>
            <description>Topical Gel Vehicle applied topically once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Inflammatory Lesion Counts From Baseline</title>
          <population>ITT Population, LOCF</population>
          <units>lesion count change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.4" spread="12.46"/>
                    <measurement group_id="O2" value="-0.7" spread="12.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Ranked Change in Inflammatory Lesion Counts = Ranked Baseline Inflammatory Lesion Counts, Analysis Center, Treatment</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Adapalene/Benzoyl Peroxide</title>
          <description>Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5% applied topically once daily for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Topical Gel Vehicle</title>
          <description>Topical Gel Vehicle applied topically once daily for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>RIGHT FRONTAL ARTERIOVENOUS MALFORMATION</sub_title>
                <description>occurred on Day 2, resolved on Day 29 and the subject completed the study as planned.Severe, nonrelated Adverse Events (AE), Inpatient hospitalization.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <limitations_and_caveats>LOCF data were used for primary efficacy and secondary efficacy data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Michael Graeber, MD</name_or_title>
      <organization>Galderma</organization>
      <phone>609-860-8201</phone>
      <email>michael.graeber@galderma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

